a-synuclein PET Imaging: From Clinical Utility in Multiple System Atrophy to the Possible Diagnosis of Parkinson’s Disease

a-synuclein PET Imaging: From Clinical Utility in Multiple System Atrophy to the Possible Diagnosis of Parkinson’s Disease

The development of PET tracers for the detection of pathological alpha-synuclein (a-synuclein) has the potential to revolutionize the diagnosis, monitoring, and therapeutic interventions of synucleinopathies, including Parkinson’s disease. The journey toward identifying effective PET imaging agents,...

Full description

Saved in:

Bibliographic Details
Main Author:	Francesca Capotosti
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Cells
Subjects:	alpha-synuclein Parkinson’s disease multiple system atrophy positron emission tomography
Online Access:	https://www.mdpi.com/2073-4409/14/11/834
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy
by: James A. Wiseman, et al.
Published: (2025-02-01)

Clinical utility of synuclein skin biopsy in the diagnosis and evaluation of synucleinopathies
by: Jonathan R. Isaacson, et al.
Published: (2024-12-01)

Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
by: Baoyi Li, et al.
Published: (2024-10-01)

Synthesis and preliminary biological evaluation of a novel PET tracer for α-synuclein PET imaging
by: WANG Ce, et al.
Published: (2024-10-01)

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
by: Sara Lucas-Del-Pozo, et al.
Published: (2025-10-01)

Neuropathological stages of neuronal, astrocytic and oligodendrocytic alpha-synuclein pathology in Parkinson’s disease
by: Maria Otero-Jimenez, et al.
Published: (2025-02-01)

Pilot Study of [<sup>11</sup>C]HY-2-15: A Mixed Alpha-Synuclein and Tau PET Radiotracer
by: Chia-Ju Hsieh, et al.
Published: (2025-07-01)

Intracellular Inclusions Induced by Patient-Derived and Amplified α-Synuclein Aggregates Are Morphologically Indistinguishable
by: Rabab Al-Lahham, et al.
Published: (2025-05-01)

Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis
by: Nylund Marjo, et al.
Published: (2025-08-01)

Characteristics of cerebral glucose metabolism in patients with cognitive impairment in multiple system atrophy
by: Bin Chen, et al.
Published: (2025-03-01)

Novel approaches targeting α-Synuclein for Parkinson's Disease: Current progress and future directions for the disease-modifying therapies
by: David Baggett, et al.
Published: (2024-12-01)

Neuromodulation influences T lymphocyte calcium signaling and alpha synuclein clearance: implications for Parkinson’s disease
by: Alysia Ross, et al.
Published: (2025-07-01)

The interplay between α-synuclein aggregation and necroptosis in Parkinson’s disease: a spatiotemporal perspective
by: Haoran Xiang, et al.
Published: (2025-04-01)

Trans-sodium crocetinate ameliorates Parkinson-like disease caused by bisphenol A through inhibition of apoptosis and reduction of α-synuclein in rats
by: Majid Keshavarzi, et al.
Published: (2025-02-01)

Fasudil inhibits α-synuclein aggregation through ROCK-inhibition-mediated mechanisms
by: Lucia Lage, et al.
Published: (2025-03-01)

Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model
by: Fiona Weiss, et al.
Published: (2024-12-01)

Recursive seed amplification detects distinct α-synuclein strains in cerebrospinal fluid of patients with Parkinson’s disease
by: Stefan Bräuer, et al.
Published: (2025-01-01)

The G209A mutation in the alpha-synuclein gene in Brazilian families with Parkinson's disease Mutação G209A no gene da alfa-sinucleína em famílias brasileiras com doença de Parkinson
by: Hélio A.G. Teive, et al.
Published: (2001-09-01)

Targeting the gut to protect from ascending pathology in the paraquat and lectin model of Parkinson's disease
by: Caroline Swain, et al.
Published: (2024-11-01)

Does Parkinson's disease start in the gut?
by: Oscar S. Gershanik

The interplay of iron, oxidative stress, and α-synuclein in Parkinson’s disease progression
by: Yan Chen, et al.
Published: (2025-04-01)

Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform
by: Martin Schuler, et al.
Published: (2025-04-01)

Positron emission tomography tracers for synucleinopathies
by: Jie Xiang, et al.
Published: (2025-01-01)

Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species
by: Mª Salomé Sirerol-Piquer, et al.
Published: (2025-03-01)

Erythrocytic α-Synuclein in Parkinson’s Disease and Progressive Supranuclear Palsy—A Pilot Study
by: Costanza Maria Cristiani, et al.
Published: (2024-11-01)

Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants
by: Linnea Charlotta Hjelm, et al.
Published: (2025-05-01)

From the baker to the bedside: yeast models of Parkinson's disease
by: Regina Menezes, et al.
Published: (2015-07-01)

Glutamate-associated research in Parkinson’s disease: a bibliometric analysis
by: Yan-Jun Chen, et al.
Published: (2025-08-01)

Synapses-associated research in Parkinson’s disease: an explored trends analysis
by: Yan-Jun Chen, et al.
Published: (2025-04-01)

Astrocytes-associated research in Parkinson’s disease: an explored trends analysis
by: Yan-Jun Chen, et al.
Published: (2025-03-01)

The Parkinson’s disease-associated protein α-synuclein disrupts stress signaling – a possible implication for methamphetamine use?
by: Shaoxiao Wang, et al.
Published: (2014-03-01)

c-Abl Inhibitors in Parkinson’s: Exploring Hypotheses on Alpha-Synuclein Modulation
by: Jyutia Nargish, et al.
Published: (2025-04-01)

Phosphorylated alpha-synuclein distribution in the colonic enteric nervous system of patients with diverticular disease
by: François Cossais, et al.
Published: (2025-06-01)

Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein—An In Silico and Experimental Approach to Parkinson’s Disease
by: Sophia A. Frantzeskos, et al.
Published: (2024-11-01)

Brain structural features with functional priori to classify Parkinson’s disease and multiple system atrophy using diagnostic MRI
by: Kai Zhou, et al.
Published: (2025-07-01)

Parkinson’s Disease: A Narrative of the Evolving Understanding of the Role of α-Synuclein in Screening
by: Alan D. Kaye, et al.
Published: (2024-11-01)

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology
by: Dag Sehlin, et al.
Published: (2025-03-01)

N-acetylation of α-synuclein enhances synaptic vesicle clustering mediated by α-synuclein and lysophosphatidylcholine
by: Chuchu Wang, et al.
Published: (2024-12-01)

THE LEVEL OF Α-SYNUCLEIN IN THE PLASMA AS A BIOMARKER OF PAIN IN PARKINSON'S DISEASE TAKING INTO ACCOUNT THE MOTOR SUBTYPES
by: K.A. Tarianyk
Published: (2024-07-01)

The role of PET/CT in the diagnosis and response assessment in patients with multiple myeloma
by: A. E. Pankratov, et al.
Published: (2021-09-01)